甲胎蛋白衰减趋势可预测甲胎蛋白阳性肝细胞癌患者术后预后
该研究分析238例接受根治性肝切除术的甲胎蛋白阳性肝细胞癌患者(2016-2023),基于术前甲胎蛋白水平和术后系列甲胎蛋白测量值及间隔时间计算甲胎蛋白半衰期,以约4天为阈值将患者分为快速衰减组(≤4天)和延迟衰减组(>4天)。结果显示延迟衰减组中国肝癌分期更晚、微血管侵犯发生率更高、肿瘤直径更大、术前甲胎蛋白水平更高,且无复发生存率和总生存率均显著更差;多因素Cox分析证实甲胎蛋白半衰期延长是术后复发的独立危险因素(HR=1.653,95%CI:1.165-2.346,P=.005)。
要点
- 术前甲胎蛋白>100 ng/mL的肝细胞癌患者术后预后显著更差
- 甲胎蛋白半衰期>4天提示肿瘤分期更晚、侵袭性更强、预后更差
- 甲胎蛋白半衰期延长是根治性切除术后复发的独立危险因素
核心结论
- 甲胎蛋白半衰期延长与肝细胞癌更晚的肿瘤分期和侵袭性生物学行为相关,提示根治性切除术后预后不良。
研究设计与样本
- 回顾性分析238例接受根治性肝切除术的甲胎蛋白阳性肝细胞癌患者(2016-2023),基于术前甲胎蛋白水平、术后系列甲胎蛋白测量值及评估间隔计算甲胎蛋白半衰期。
- 以约4天为阈值将患者分为快速甲胎蛋白衰减组(≤4天)和延迟甲胎蛋白衰减组(>4天),比较两组临床病理特征和生存结局。
- 采用单因素和多因素Cox比例风险模型识别术后肝细胞癌复发的独立危险因素,并实施倾向性评分匹配以校正基线临床病理差异。
- 主要终点为无复发生存率。
主要发现
- 术前甲胎蛋白>100 ng/mL的肝细胞癌患者术后预后显著差于甲胎蛋白水平较低者。
- 延迟甲胎蛋白衰减组中国肝癌分期更晚、微血管侵犯发生率更高、肿瘤直径更大、术前血清甲胎蛋白水平更高。
- 延迟甲胎蛋白衰减组无复发生存率和总生存率均显著劣于快速甲胎蛋白衰减组。
- 多因素Cox分析证实甲胎蛋白半衰期延长是复发的独立危险因素(HR=1.653,95%CI:1.165-2.346,P=.005)。
关键数值与推荐
- 甲胎蛋白半衰期阈值约4天,≤4天为快速衰减,>4天为延迟衰减。
- 术前甲胎蛋白>100 ng/mL者术后预后显著更差。
- 甲胎蛋白半衰期延长为独立复发危险因素(HR=1.653,95%CI:1.165-2.346,P=.005)。
临床怎么用
- 对甲胎蛋白阳性肝细胞癌根治性切除术后患者,应监测术后系列甲胎蛋白水平并计算半衰期以辅助预后评估。
- 甲胎蛋白半衰期>4天者提示肿瘤侵袭性较强、复发风险较高,可能需要更密切的术后随访和个体化辅助治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although preoperative alpha-fetoprotein levels predict hepatocellular carcinoma prognosis, the significance of perioperative alpha-fetoprotein dynamics remains unclear. METHODS: We analyzed 238 alpha-fetoprotein-positive hepatocellular carcinoma patients undergoing curative hepatectomy (2016-2023). The alpha-fetoprotein half-life was derived from preoperative alpha-fetoprotein levels, postoperative serial alpha-fetoprotein measurements, and the intervals between assessments. Interindividual variability in serum alpha-fetoprotein half-life (median of approximately 4 days) was observed among patients with elevated alpha-fetoprotein levels. Consequently, patients were stratified into rapid alpha-fetoprotein decay (≤4 days) and delayed alpha-fetoprotein decay (>4 days) groups based on this threshold. Clinicopathologic characteristics and survival outcomes were compared between the cohorts. Univariate and multivariate Cox proportional hazards models were used to identify independent risk factors for postoperative hepatocellular carcinoma recurrence. Propensity score matching was implemented to address baseline clinicopathologic disparities. The primary endpoint was recurrence-free survival. RESULTS: Patients with hepatocellular carcinoma and preoperative alpha-fetoprotein levels >100 ng/mL exhibited significantly worse postoperative prognosis compared with those with lower alpha-fetoprotein levels. The delayed alpha-fetoprotein decay group demonstrated advanced China liver cancer stage, higher incidence of microvascular invasion, larger tumor diameters, and elevated preoperative serum alpha-fetoprotein levels. Consequently, the delayed alpha-fetoprotein decay group showed significantly inferior recurrence-free survival and overall survival compared with the rapid alpha-fetoprotein decay group. Multivariate Cox analysis confirmed prolonged alpha-fetoprotein half-life as an independent recurrence risk factor (hazard ratio = 1.653, 95% confidence interval: 1.165-2.346, P = .005). CONCLUSION: Prolonged alpha-fetoprotein half-life was associated with advanced tumor stage and aggressive tumor behavior in patients with hepatocellular carcinoma, suggesting a poor prognosis after curative resection.
引用
- Pang S, Cheng L, Shi Y, et al. Attenuation trend of alpha-fetoprotein predicts postoperative prognosis in alpha-fetoprotein-positive hepatocellular carcinoma patients. Surgery. 2025. PMID: 40967115. doi:10.1016/j.surg.2025.109671
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。